NasdaqGS - Nasdaq Real Time Price • USD
Tarsus Pharmaceuticals, Inc. (TARS)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 5:32 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 7 |
| Avg. Estimate | -1.2 | -1.07 | -4.18 | -1.88 |
| Low Estimate | -1.32 | -1.31 | -4.93 | -3.57 |
| High Estimate | -0.89 | -0.92 | -3.3 | -0.35 |
| Year Ago EPS | -0.88 | -1.17 | -4.62 | -4.18 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 7 |
| Avg. Estimate | 17.83M | 23.59M | 99.74M | 200.61M |
| Low Estimate | 15.71M | 18.99M | 75M | 175M |
| High Estimate | 20.1M | 26.27M | 113.51M | 239.87M |
| Year Ago Sales | 3.12M | -- | 17.45M | 99.74M |
| Sales Growth (year/est) | 471.50% | -- | 471.70% | 101.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.94 | -1.08 | -1.36 | -1.36 |
| EPS Actual | -0.88 | -1.17 | -1.28 | -1.31 |
| Difference | 0.06 | -0.09 | 0.08 | 0.05 |
| Surprise % | 6.40% | -8.30% | 5.90% | 3.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.2 | -1.07 | -4.18 | -1.88 |
| 7 Days Ago | -1.2 | -1.07 | -4.18 | -1.88 |
| 30 Days Ago | -1.25 | -1.12 | -4.39 | -2.14 |
| 60 Days Ago | -1.39 | -1.33 | -4.88 | -2.18 |
| 90 Days Ago | -1.37 | -1.34 | -4.91 | -2.19 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 2 | 2 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | TARS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -36.40% | -- | -- | 5.40% |
| Next Qtr. | 8.50% | -- | -- | 10.90% |
| Current Year | 9.50% | -- | -- | 4.50% |
| Next Year | 55.00% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -20.70% | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Jefferies: Buy to Buy | 3/6/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 2/29/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/28/2024 |
| Maintains | Barclays: Overweight to Overweight | 2/28/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 2/28/2024 |
| Initiated | Goldman Sachs: Neutral | 11/20/2023 |
Related Tickers
CNTA Centessa Pharmaceuticals plc
8.92
-0.11%
KRYS Krystal Biotech, Inc.
156.88
+0.77%
DYN Dyne Therapeutics, Inc.
24.73
+4.37%
SYRE Spyre Therapeutics, Inc.
33.56
+3.36%
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
PHAT Phathom Pharmaceuticals, Inc.
9.18
+0.88%
MRUS Merus N.V.
45.04
+0.24%
APGE Apogee Therapeutics, Inc.
47.13
+2.77%
ARQT Arcutis Biotherapeutics, Inc.
8.47
-1.40%
ELYM Eliem Therapeutics, Inc.
3.9800
+17.40%